New CCO starts in June

Marc Clausse has been working in the life sciences sector for more than 25 years. He has in-depth expertise in the fields of specialty medicines, oncology and rare diseases.  Most recently, he served as VP of International Strategy & Operations and UK General Manager at Mirum Pharmaceuticals. In this role, he co-led the development of the regional sales infrastructure, acted as a key decision-maker in market access negotiations and established sales partnerships across Europe and other international markets.

Prior to that, he served as VP and Head of Oncology for the UK and Ireland at GSK, where he steered the ovarian cancer portfolio to a market-leading position and led the integration of Tesaro UK following its acquisition in 2018. Previously, in his role as Tesaro’s General Manager UK & Ireland, he had overseen all commercial, medical and market access-related functions.

In his new role at Santhera, he succeeds Geert Jan van Daal. Van Daal joined the company in 2015 and became CCO in 2024. Now he will retire, but before, he is supporting the transition to the new CCO in an advisory role.